STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #722 by analyst upside · 2026-06-27
NUVB
Nuvation Bio Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+118.3%
implied upside to consensus target
Current Price $5.65
Consensus Target $12.33
Bull Target $20.0
Bear Target $7.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
1
Sell
0
52-Week Low $1.86
52-Week High $9.75
YTD Return -34.1%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -94.2x
EPS (TTM) $-0.43
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $143M
Profit Margin -102.1%
52-WEEK RANGE
52-Week Low $1.86
52-Week High $9.75
Current Price $5.65
Bear Target $7.0
Bull Target $20.0
● Now $5.65 ● Target $12.33
TRADING DATA
Avg Volume 4.6M
YTD Return -34.1%
Analyst Count 9
Consensus Buy
Upside to Target +118.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Nuvation Bio Inc. (NUVB) is currently trading at $5.65 with a Wall Street consensus price target of $12.33, implying potential upside of 118.3% over the next 12 months. 9 analysts currently cover NUVB, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $7.0.

NUVB operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 34.1% year-to-date and is currently trading near the lower end of its 52-week range of $1.86 – $9.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NUVB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital reit
Outperform → Outperform 2026-05-05 Building track record
Wedbush reit
Outperform → Outperform 2026-05-05 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-05-05 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-04-16 Building track record
Wedbush reit
Outperform → Outperform 2026-04-02 Building track record
Wedbush reit
Outperform → Outperform 2026-03-27 Building track record
UBS — Reiterated
Neutral → Neutral 2026-03-03 33% win rate (6 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-03-03 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →